MMAE

MMAE

MMAE is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin. It is a very potent antimitotic agent that inhibits cell division by blocking the polymerization of tubulin. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

Molecular structure of the compound BP-22278
    • Unit
    • Price
    • Qty
    • 100 MG
    • $280.00
    • 250 MG
    • $490.00
    • 500 MG
    • $680.00
    • 1 G
    • $995.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire

Product Citations

  1. Li, W. F., Chiang, M. F., Weng, H. C., Yang, J. J., Wu, H. S., Wu, S. Y., ... & Lai, M. T. (2025). OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. Molecular Cancer Therapeutics, 24(2), 163-175.
    https://doi.org/10.1158/1535-7163.MCT-24-0588
  2. Samantha RB, Courtney PJ, Siteng F, et al. Thiolation of Q295: Site-Specific Conjugation of Hydrophobic Payloads without the Need for Genetic Engineering. Molecular Pharmaceuticals. 2019; 16(6): pp. 2795-2805.
    https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.9b00323